We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Bracco

Offers products, injectors and solutions portfolio for all diagnostic applications from constrast media to medical de... read more Featured Products: More products

Download Mobile App




Groundbreaking AI-Powered Software Significantly Enhances Brain MRI

By MedImaging International staff writers
Posted on 25 Oct 2024
Print article
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)

Contrast-enhanced magnetic resonance imaging (MRI) utilizes contrast agents to illuminate specific tissues or abnormalities, leading to improved visualization and more comprehensive information. Integrating artificial intelligence (AI) into this process could enhance image interpretation accuracy and efficiency, bolster diagnostic capabilities, and optimize patient care. Now, a groundbreaking AI-powered software has been designed to significantly improve brain MRI, particularly in detecting small and poorly enhanced lesions.

AiMIFY, a collaborative software from Bracco Diagnostics (Milan, Italy) and Subtle Medical (Menlo Park, CA, USA), employs advanced AI technology to increase the contrast enhancement of brain MR images by up to two times the level achieved with a standard dose of gadolinium-based contrast agents (GBCAs). This enhancement allows radiologists and neuroradiologists to obtain clearer, more detailed images, enhancing the visibility of both small and large lesions compared to standard post-contrast images. The software's efficacy has been validated across a wide range of test data, encompassing various patient demographics, pathologies, lesion sizes, MRI scanner vendors, sequences, and acquisition orientations. AiMIFY has received FDA clearance as a Class II software as a medical device (SaMD) specifically for brain MRI.

"This FDA clearance marks a significant milestone for our innovative product, showcasing its potential to transform MRI," said Fulvio Renoldi Bracco, Vice Chairman & Chief Executive Officer of Bracco Imaging S.p.A. "By integrating Bracco's expertise in contrast imaging with Subtle Medical's cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients."

"We partnered with Bracco to unlock the potential that AI brings to medical imaging," added Ajit Shankaranarayanan, PhD, Chief Product Officer at Subtle Medical. "The FDA clearance represents a significant milestone for both companies, as we join forces to empower radiological professionals and improve outcomes for patients worldwide with this innovative AI-powered medical imaging solution."

Related Links:
Bracco Diagnostics
Subtle Medical

Computed Tomography System
Aquilion ONE / INSIGHT Edition
Radiation Therapy Treatment Software Application
Elekta ONE
Digital X-Ray Detector Panel
Acuity G4
New
Ultrasonic Pocket Doppler
SD1

Print article

Channels

Ultrasound

view channel
Image: Ultrasound detection of vascular changes post-RT corresponds to shifts in the immune microenvironment (Photo courtesy of Theranostics, DOI:10.7150/thno.97759)

Ultrasound Imaging Non-Invasively Tracks Tumor Response to Radiation and Immunotherapy

While immunotherapy holds promise in the fight against triple-negative breast cancer, many patients fail to respond to current treatments. A major challenge has been predicting and monitoring how individual... Read more

Nuclear Medicine

view channel
Image: Autoradiography images showing binding of [18F]flortaucipir, [18F]MK6240, and [18F]PI2620 in prefrontal cortex, hippocampus, and cerebellum (A) and in whole-brain hemisphere (B) of control and AD brains (Photo courtesy of UFRGS)

Next-Gen Tau Radiotracers Outperform FDA-Approved Imaging Agents in Detecting Alzheimer’s

In Alzheimer’s disease, tau tangles are closely linked to cognitive decline: the greater the number of tangles, the more severe the cognitive impairment. By measuring the amount of tau in brain tissue... Read more

General/Advanced Imaging

view channel
Image: The rugged and miniaturized CT scanner is being designed for use beyond a typical hospital setting (Photo courtesy of Micro-X)

World’s First Mobile Whole-Body CT Scanner to Provide Diagnostics at POC

Conventional CT scanners dominate the global medical imaging market, holding approximately 30% of the market share. These scanners are the current standard for various diagnostic applications, including... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.